GSK-3 inhibitors for Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 11, 2007, Pages 1527-1533

  Avila, Jesús ^a   Hernández, Félix ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; Amyloid peptide; GSK 3; Lithium; Tau

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM; TAU PROTEIN;

ALZHEIMER DISEASE; DEATH; GENE OVEREXPRESSION; HUMAN; MOOD DISORDER; NEUROFIBRILLARY TANGLE; NONHUMAN; PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 36148942761     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.11.1527     Document Type: Review

References (85)

1. Alzheimer A. Ueber eigenartige Krankheitsfaelle des spaeteren Alters. Z. Gesamte Neurol. Psychiatr. 4, 356-386 (1911). • First step in the study of the disease.
2. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757-2763 (1985). •• Key paper describing the main composition of senile plaques.
3. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984). •• Key paper describing the main composition of senile plaques.
4. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505 (1998).
5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913-4917 (1986). •• Key paper describing phosphorylated tau in Alzheimer's disease (AD).
6. Morishima-Kawashima M, Hasegawa M, Takio K et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829 (1995). • Good description of tau phosphorylation sites.
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002). • Main hypothesis for the origin of AD.
8. Murayama O, Tomita T, Nihonmatsu N et al. Enhancement of amyloid-β 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 265, 61-63 (1999).
9. Dermaut B, Kumar-Singh S, Engelborghs S et al. A novel presenilin 1 mutation associated with Pick's disease but not β-amyloid plaques. Ann. Neurol. 55, 617-626 (2004).
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239-259 (1991).
11. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639 (1992). •• One of the classic studies showing that neurofibrillary tangles (NFTs) are the histopathological hallmark that correlates with the severity of the disease.
12. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci. 11, 205-242 (1970).
13. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. (Berl.) 74, 209-225 (1987).
14. Santacruz K, Lewis J, Spires T et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005). • Noteworthy paper on the relationship among NFTs and cognitive functions in AD.
15. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 580, 2922-2927 (2006).
16. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 580, 4842-4850 (2006).
17. Alonso A C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103, 8864-8869 (2006).
18. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107, 519-527 (1980).
19. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9, 2431-2438 (1990). •• Key paper on the molecular features of glycogen synthase kinase (GSK)-3.
20. Hansen L, Arden KC, Rasmussen SB et al. Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM. Diabetologia 40, 940-946 (1997).
21. Shaw PC, Davies AF, Lau KF et al. Isolation and chromosomal mapping of human glycogen synthase kinase-3α and -3β encoding genes. Genome 41, 720-727 (1998).
22. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem. 81, 1073-1083 (2002).
23. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95-102 (2004). • Excellent review on GSK-3.
24. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
25. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon VA. Chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophosphorylation. Mol. Cell 24, 627-633 (2006).
26. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804 (1997).
27. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase-3β in cellular signaling. Prog. Neurobiol. 65, 391-426 (2001). • Good review on GSK-3.
28. Hernandez F, Perez M, Lucas JJ, Mata AM, Bhat R, Avila J. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J. Biol. Chem. 279, 3801-3806 (2004).
29. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8, 593-596 (2001).
30. Dajani R, Fraser E, Roe SM et al. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732 (2001).
31. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3β. Biochemistry 45, 3134-3145 (2006).
32. Noble W, Olm V, Takata K et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (2003).
33. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167, 99-105 (1997).
34. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116, 671-682 (2004).
35. Amit S, Hatzubai A, Birman Y et al. Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076 (2002).
36. Liu SJ, Zhang AH, Li HL et al. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 87, 1333-1344 (2003).
37. Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett. 358, 4-8 (1995).
38. Goñi-Oliver P, Lucas JJ, Avila J, Hernandez F. N-terminal cleavage of GSK-3 by Calpain: a new form of GSK-3 regulation. J. Biol. Chem. 282, 22406-22413 (2007). • Calpain removes the N-terminal end regulatory domain, activating GSK-3.
39. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc. Natl Acad. Sci. USA 90, 7789-7793 (1993). • Important contribution about the relationship between GSK-3 and tau.
40. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003).
41. Uemura K, Kuzuya A, Shimozono Y et al. GSK3β activity modifies the localization and function of presenilin 1. J. Biol. Chem. 282, 15823-15832 (2007).
42. Takashima A, Murayama M, Murayama O et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc. Natl Acad. Sci. USA 95, 9637-9641 (1998).
43. Zhang Z, Hartmann H, Do VM et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395, 698-702 (1998).
44. Baki L, Shioi J, Wen P et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23, 2586-2596 (2004).
45. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in Neurons. FEBS Lett. 411, 183-188 (1997). •• One of the first papers showing the effect of lithium on AD.
46. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured Neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264 (1999).
47. Takashima A, Honda T, Yasutake K et al. Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid-β peptide (25-35) enhances phosphorylation of tau in hippocampal Neurons. Neurosci. Res. 31, 317-323 (1998).
48. Wang ZF, Li HL, Li XC et al. Effects of endogenous β-amyloid overproduction on tau phosphorylation in cell culture. J. Neurochem. 98, 1167-1175 (2006).
49. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5, 301-308 (2003). •• First paper showing the effect of lithium on tau aggregation in an AD mouse model.
50. Noble W, Planel E, Zehr C et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990-6995 (2005).
51. Ishiguro K, Omori A, Takamatsu M et al. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 148, 202-206 (1992).
52. Ishiguro K, Shiratsuchi A, Sato S et al. Glycogen synthase kinase-3β is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167-172 (1993). • Key paper describing GSK-3 as one of the main tau kinases.
53. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384 (2004).
54. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with Neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. (Berl.) 104, 583-591 (2002).
55. Pei JJ, Braak E, Braak H et al. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019 (1999).
56. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70-78 (1997).
57. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl.) 92, 232-241 (1996).
58. Jackson GR, Wiedau-Pazos M, Sang TK et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519 (2002).
59. Brownlees J, Irving NG, Brion JP et al. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes. Neuroreport 8, 3251-3255 (1997).
60. Spittaels K, Van den Haute C, Van Dorpe J et al. Neonatal Neuronal overexpression of glycogen synthase kinase-3β reduces brain size in transgenic mice. Neuroscience 113, 797-808 (2002).
61. Li B, Ryder J, Su Y et al. Overexpression of GSK3βS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3β transgenic mice. Transgenic Res. 13, 385-396 (2004).
62. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27-39 (2001). • Animal model to study the role of GSK-3β in different brain areas.
63. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally overexpress GSK-3β in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533 (2002).
64. Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090 (2006).
65. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez, F. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 27, 1258-1268 (2006).
66. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett, J.R. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406, 86-90 (2000).
67. Gomez-Sintes R, Hernandez F, Bortolozzi A et al. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J. 26, 2743-2754 (2007). • Mice overexpressing a dominant negative-GSK-3β form show us that extensive GSK-3 inhibition can induce apoptosis.
68. Meares GP, Jope RS. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J. Biol. Chem. 282, 16989-17001 (2007).
69. Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase-3β as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc. Natl Acad. Sci. USA 92, 8498-8502 (1995).
70. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93, 8455-8459 (1996).
71. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290, 967-972 (2002).
72. Nakashima H, Ishihara T, Suguimoto P et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. (Berl.) 110, 547-556 (2005).
73. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445-1455 (2006).
74. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675 (2007).
75. Bhat R, Xue Y, Berg S et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945 (2003).
76. Leclerc S, Garnier M, Hoessel R et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260 (2001).
77. Coghlan MP, Culbert AA, Cross DA et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803 (2000).
78. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299 (2002).
79. Rao KV, Donia MS, Peng J et al. Manzamine B and E and Ircinal A related alkaloids from an Indonesian Acnthostrong ylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's disease. J. Nat. Prod. 69(7), 1034-1040 (2006).
80. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6, 464-479 (2007).
81. Hooper C, Markevich V, Plattner F et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J. Neurosci. 25, 81-86 (2007).
82. Peineau S, Taghibiglou C, Bradley C et al. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53, 703-717 (2007).
83. Son H, Yu IT, Hwang SJ et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J. Neurochem. 85, 872-881 (2003).
84. Lau KF, Miller CC, Anderton BH, Shaw PC. Molecular cloning and characterization of the human glycogen synthase kinase-3β promoter. Genomics 60, 121-128 (1999).
85. Russ C, Lovestone S, Powell JF. Identification of sequence variants and analysis of the role of the glycogen synthase kinase-3β gene and promoter in late onset Alzheimer's disease. Mol. Psychiatry 6, 320-324 (2001).